^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Published date:
11/04/2021
Excerpt:
In Cohort #4 (75 mg), a R/R AML patient with DNMT3A mutation achieved a Complete Remission (CR) being in disease progression under venetoclax/decitabine treatment….RVU120 shows preliminary signs of efficacy in AML and HR-MDS with a tolerable safety profile, including a CR and an ER in patients previously treated with venetoclax combination therapy.
DOI:
10.1182/blood-2021-151030